CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 11 No. 3
Pages: 1  2  3  
Next
 

Low-Dose Amifostine May Prevent Platinum Neurotoxicity

March 1, 2002

NEW YORK—Repeated low-dose administration of amifostine(Drug information on amifostine) (Ethyol) is being studied in a randomized, multi-center, community-based trial in an attempt to prevent neurotoxicity caused by platinum-based chemotherapy.
David Alberts, MD, and Martee Hensley, MD, discussed the new study at the Ethyol Emerging Neuropathy Trial Investigator Meeting.

How Amifostine Works

Dr. Alberts, professor of medicine, pharmacology, and public health, and associate dean for research at the University of Arizona College of Medicine and Arizona Cancer Center, Tucson, explained that amifostine is a targeted cytoprotectant for normal cells.

"Amifostine is a prodrug that is not active in vitro unless dephosphorylated to the sulfhydryl form, WR-1065, which undergoes oxidation to a symmetric disulfide, WR-33278, an extremely important cationic polyamine that protects DNA during chemotherapy and radiation therapy," he said.

Amifostine is generally not dephosphorylated by tumors because cancers tend to have very low levels of membrane-bound alkaline phosphatase, which is required to dephosphorylate the pro-drug. "There is a 250-fold difference in the amount of alkaline phosphatase on the cell membranes of normal human lung fibroblasts compared to a non-small-cell lung cancer (NSCLC) cell line," Dr. Alberts said (Figure 1).

As a result, he said, on normal cells, dephosphorylation produces WR-1065, "which is pulled into the cell and can absorb oxygen free radicals, neutralize the DNA-binding moieties of platinum-containing and alkylating agents, protect DNA against radiation damage, and induce DNA repair mechanisms, possibly by stripping away platinum adducts."

Dr. Alberts said that several different types of normal tissue could potentially be protected by amifostine against chemotherapy or radiation. The drug is FDA approved specifically to protect against nephrotoxicity from cisplatin(Drug information on cisplatin) (Platinol) in ovarian cancer and NSCLC patients, as well as to protect against radiation-induced xerostomia, he said.

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy